Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €18.66 EUR
Change Today -0.32 / -1.69%
Volume 144.0K
REC On Other Exchanges
Symbol
Exchange
REC is not on other exchanges.
As of 11:30 AM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

recordati spa (REC) Snapshot

Open
€18.50
Previous Close
€18.98
Day High
€18.93
Day Low
€18.50
52 Week High
07/2/15 - €19.87
52 Week Low
08/8/14 - €11.30
Market Cap
3.9B
Average Volume 10 Days
234.4K
EPS TTM
€0.83
Shares Outstanding
209.1M
EX-Date
04/20/15
P/E TM
22.5x
Dividend
€0.50
Dividend Yield
2.68%
Current Stock Chart for RECORDATI SPA (REC)

Related News

No related news articles were found.

recordati spa (REC) Related Businessweek News

No Related Businessweek News Found

recordati spa (REC) Details

Recordati S.p.A. engages in the research, development, manufacture, marketing, and sale of pharmaceuticals. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, cosmetics, dermatology, dietary supplements, musculo-skeletal disorders and analgesia, pregnancy test, urology, OTC/non-prescription pharmaceuticals, allergy, antiinfectives, central nervous system, endocrinology, gastrointestinal, gynecology, obstetrics, nutrition and related areas, immunosuppressants, pediatrics, pneumology, hematology, oncology, respiratory, and generics. It primarily offers Zanidip (lercanidipine), a calcium channel blocker for the treatment of hypertension. The company’s product development pipeline includes Carbaglu, which is approved in the European Union and is under Phase III clinical trial in the United States for the treatment of organic acidemias; Zanipress that is approved in the European Union to treat essential hypertension; and Cystadrops that is under pre-registration in the European Union for the treatment of ocular cystinosis. Its product development pipeline also includes methadone that is under phase III b clinical trial to treat cancer related pain; Citrafleet, which is under Phase III clinical trials for colonoscopy; Graspa, which is under pre-filing stage in the European Union for acute lymphoblastic leukemia, as well as under phase II b clinical trials for acute myeloid leukemia; and REC 0438 that is under phase I clinical trial in the European Union for treating overactive bladder in patients with spinal lesions. Further, the company produces pharmaceutical chemicals, such as active pharmaceutical ingredients and intermediates. It has operations in Europe, Australasia, Africa, and the United States. The company was founded in 1926 and is headquartered in Milan, Italy.

3,923 Employees
Last Reported Date: 03/6/15
Founded in 1926

recordati spa (REC) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: €1.2M
Compensation as of Fiscal Year 2014.

recordati spa (REC) Key Developments

Recordati SpA Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-09-2015

Recordati SpA Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-09-2015 . Venue: Terranea Resort, Rancho Palos Verdes, California, United States.

Apricus Biosciences Unveils Erectile Dysfunction Treatment Cream Virirec in Spain Through Recordati

Apricus Biosciences reported the availability of its novel topical on-demand treatment cream for treating erectile dysfunction Virirec in Spain through Recordati. In the past, Apricus has signed an exclusive license agreement with Recordati S.p.A. to market Vitaros in Spain, Russia, Turkey, Ireland and certain other European and African countries and received an upfront payment of USD 2.5 million. As part of the agreement, Apricus is eligible to receive up to approximately USD 38.5 million from Recordati in additional milestones, plus double-digit tiered royalties based on Recordati's net sales of the product in the Territory. In exchange, Recordati has the exclusive right to commercialise Virirec in the Territory. Additionally, Virirec is marketed in other European countries as Vitaros and in Belgium as Vytaros. This is the fifth territory in the EU in which the product has been launched following launches in the UK, Germany, Sweden and Belgium. The product is approved in ten countries in Europe, including France and Italy. According to the company, Vitaros is a topical ED cream that delivers rapid onset (generally 5-15 minutes), treatment duration of approximately 1 hour and a favorable safety profile. Its local delivery provides an attractive alternative for all patients, but particularly those with complications that preclude them from using the orally delivered systemic treatments or who prefer to not use the injectable forms of alprostadil.

Recordati SpA Reports Earnings Results for the First Quarter Ended March 31, 2015; Re-Affirms Earnings Guidance for the Year 2015

Recordati SpA reported earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of €275.7 million compared to €260.4 million, operating income of €73.5 million compared to €62.2 million, pre-tax income of €69.7 million compared to €58.1 million net income attributable to Equity holders of the parent of €52.0 million or €0.248 per diluted share compared to €42.8 million or €0.202 per diluted share for the last year. EBITDA was €82.8 million, up 15.9% over the same period of the preceding year. For the full year 2015, the company confirm expectations to achieve sales of more than €1,000 million, operating income of around €250 million and net income of around €175 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REC:IM €18.66 EUR -0.32

REC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.135.80 CHF -2.50
Faes Farma SA €2.28 EUR -0.03
H Lundbeck A/S kr136.00 DKK -0.30
Shire PLC 5,230 GBp 0.00
Procter & Gamble Co/The $80.05 USD +0.12
View Industry Companies
 

Industry Analysis

REC

Industry Average

Valuation REC Industry Range
Price/Earnings 24.1x
Price/Sales 4.0x
Price/Book 4.6x
Price/Cash Flow 24.1x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECORDATI SPA, please visit www.recordati.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.